Millennium Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Millennium Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,000	Closed	-$1.53M	–	7615
2022 Q1	$1.53M	Buy	+25,000	New	+$1.3M	﹤0.01%	4114
2021 Q4	–	Sell	-32,200	Closed	-$1.2M	–	7491
2021 Q3	$1.2M	Buy	+32,200	New	+$1.12M	﹤0.01%	4480
2019 Q4	–	Sell	-20,000	Closed	-$149K	–	4702
2019 Q3	$149K	Buy	+20,000	New	+$192K	﹤0.01%	3872
2019 Q1	–	Sell	-12,500	Closed	-$142K	–	4400
2018 Q4	$142K	Buy	+12,500	New	+$202K	﹤0.01%	3488
2016 Q4	–	Sell	-19,500	Closed	-$297K	–	3820
2016 Q3	$297K	Buy	+19,500	New	+$788K	﹤0.01%	2817
2015 Q4	–	Sell	-225,400	Closed	-$9.03M	–	3830
2015 Q3	$9.03M	Buy	225,400 +150,000	+199%	+$4.89M	0.02%	991
2015 Q2	$2.41M	Buy	+75,400	New	+$1.91M	﹤0.01%	1795

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Millennium Management's ITCI Position: Q2 2025 in Review

Millennium Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 844,073 shares — an estimated $111M sold.

Millennium Management first reported a position in ITCI in Q1 2014 and held it in 41 quarters. The position peaked at $111M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Millennium Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Millennium Management sold 844,073 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $111M.
Millennium Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 41 quarters.
Millennium Management's Intra-Cellular Therapies Inc. position peaked at $111M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.